NEW YORK, April 22, 2015 /PRNewswire/ -- Lightlake
Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical
company developing addiction treatments based on its expertise in
opioid antagonists, announced today that Adapt Pharma Limited
("Adapt"), Lightlake's partner for treating opioid overdose with
intranasal naloxone, successfully completed a clinical study of
intranasal naloxone.
The pharmacokinetic study compared intranasal naloxone with an
injectable formulation of naloxone. The study met its objectives
and demonstrated the intranasal formulation of naloxone delivered
the targeted naloxone dose as expected. Naloxone is a U.S. Food and
Drug Administration (FDA) approved agent that reverses the effects
of opioid overdose. Presently, all FDA approved formulations of
naloxone are injectable products. Adapt is collaborating with the
U.S. National Institute on Drug Abuse (NIDA) to develop a nasal
naloxone formulation that would be suitable for use in the
community setting by non-medically trained personnel.
"This important study builds on the first NIDA Lightlake
collaborative pharmacokinetic study. It continues to demonstrate
that nasal naloxone is a very promising treatment for the reversal
of opioid overdose with great potential to be used in the
community," stated Arvind Agrawal,
Executive Vice President, Medical Affairs, at Lightlake. He
added, "We have found that many caregivers in the community setting
worry about accessing and administering injectable naloxone.
Pharmacokinetic studies provide a regulatory path to bridging
between formulations. Thus nasal naloxone could provide
non-medically trained personnel with a simple and easily accessible
tool to prevent death due to opioid overdose."
According to CDC WONDER, an information resource of the Centers
for Disease Control and Prevention (CDC), opioid overdose led to
the loss of over 26,000 lives in America in 2013, a four-fold
increase since 1999. The majority of deaths arose in a community
setting (mostly at home) and approximately 70% were caused by
prescription opioids.
In December 2014, Lightlake
announced a licensing deal with a subsidiary of Adapt Pharma
Limited. In exchange for licensing its opioid overdose reversal
treatment, Lightlake could receive potential development and sales
milestone payments of more than $55
million, plus up to double-digit royalties.
About Lightlake Therapeutics Inc.
Lightlake Therapeutics Inc., a biopharmaceutical company, is
using its expertise in opioid antagonists to build a platform of
innovative intranasal naloxone solutions to common addictions and
related disorders. Lightlake has entered into a licensing deal with
a subsidiary of Adapt Pharma Limited with respect to a treatment to
reverse opioid overdoses, which have reached epidemic proportions
in the United States. Lightlake
also has collaborated on clinical trials with the National
Institute on Drug Abuse, part of the National Institutes of Health,
with respect to this treatment. In addition, Lightlake has
completed a Phase II clinical trial to treat Binge Eating Disorder.
For more information please visit:
http://www.lightlaketherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements. These
statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and
other factors that may cause our or our industry's actual results,
levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance
or achievements expressed, implied or inferred by these
forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as "may," "will,"
"should," "could," "would," "expects," "plans," "intends,"
"anticipates," "believes," "estimates," "predicts," "projects,"
"potential," or "continue" or the negative of such terms and other
comparable terminology. These statements are only predictions based
on our current expectations and projections about future events.
You should not place undue reliance on these statements. Actual
events or results may differ materially. In evaluating these
statements, you should specifically consider various factors. These
and other factors may cause our actual results to differ materially
from any forward-looking statement. We undertake no obligation to
update any of the forward-looking statements after the date of this
press release to conform those statements to reflect the occurrence
of unanticipated events, except as required by applicable law.
Corporate Contact:
Lightlake Therapeutics Inc.
445 Park Avenue, 9th Floor
New York, NY 10022
Dr. Roger Crystal, CEO
(212) 829-5546
investor.relations@lightlaketherapeutics.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lightlake-therapeutics-inc-announces-adapt-pharma-limited-successfully-completed-intranasal-naloxone-study-300069656.html
SOURCE Lightlake Therapeutics Inc.